The frequency of post-ERCP/sphincterotomy pancreatitis is between 1.3% and 7.6% in prospective studies. This range likely reflects differences in definitions of pancreatitis and methods of data collection. Methods: To identify clinical findings and enzymatic values consistent for clinical pancreatitis at 24 hours, the post-ERCP/sphincterotomy course of 1185 procedures was prospectively recorded. Patients were evaluated for pancreatic-type pain, white blood cell count, and serum amylase before and 24 hours after the procedure; pain and amylase levels were also recorded 6 to 8 hours after the procedure. CT was performed in all patients with pain associated with amylase levels greater than 3 times normal. All patients were evaluated clinically at 48 hours. Results: Pancreatic-type pain never occurred in cases with amylase levels lower than 3 times normal; it was significantly (p < 0.001) associated with amylase levels greater than 5 times normal, either 6 to 8 hours or 24 hours after the procedure. Leukocytosis and CT findings consistent with pancreatitis were observed only in patients (41.7% and 29.5%, respectively) with 24-hour amylase levels greater than 5 times normal. None of the 18 patients with pain at 24 hours and serum amylase lower than 5 times normal had symptoms that persisted at 48 hours. Twenty-five (41.7%) of the 60 patients with pain at 24 hours and amylase higher than 5 times normal had 48-hour pain at 48 hours and hyperamylasemia. 
Acute pancreatitis is still the most common complication associated with ERCP and endoscopic sphincterotomy with a frequency that ranges between 1.3% and 7.6% in prospective series of nonselected patients [1] [2] [3] [4] [5] [6] [7] ; a meta-analysis found an average overall frequency of 5.2% and 4.1% after diagnostic and therapeutic procedures, respectively. 8 The variation in frequency likely reflects different criteria for defining pancreatitis rather than differences in patient populations, indications, or endoscopic expertise. Postprocedure pancreatitis has generally been diagnosed in the largest prospective series on the basis of persistence of pancreatic-type pain at 24 hours together with serum amylase elevations of more than 2, 4,9,10 3, 7,11-17 4, 1,2 or 5 times 5,18 the upper normal limit, although in some studies these criteria have been applied 18 hours after the procedure 1,2 or irrespective of time interval. 5 The different criteria adopted by experienced endoscopists suggests difficulty in the interpretation of the clinical significance of patient symptoms and serum enzyme values in the post-ERCP period. This has led to confusion in differentiating between pancreatic reaction and clinical acute pancreatitis.
This study assessed patient outcome 48 hours after endoscopic procedures involving the major and minor duodenal papilla in a prospective series of consecutive nonselected cases to identify clinical findings and serum amylase values at 24 hours that indicated clinical pancreatitis.
MATERIAL AND METHODS
The clinical course and amylase levels after 1185 consecutive endoscopic procedures on the major and minor duodenal papilla in 1020 patients over a 36-month period were evaluated. Endoscopic procedures were performed by the same endoscopist either in a university (559) or in a university-affiliated institution (626). Patient age ranged between 5 and 94 years. All procedures (biliary or pancreatic sphincterotomy, drainage procedures, and diagnostic ERCP) were included, whether successful or unsuccessful. Not included were cases in which the papilla was not manipulated (choledocho-duodenal anastomosis or fistula), and cases in which papillary cannulation was not attempted for anatomic reasons or patient intolerance; patients with acute pancreatitis at the time of the ERCP and those recruited for clinical pharmacologic trials were also excluded.
A standard study protocol was designed and used routinely from January 1995 to December 1997 for all the endoscopic biliopancreatic procedures to prospectively evaluate post-ERCP outcome, complications, and possible patient-related or technique-related factors influencing the outcome. Criteria for definition of hyperamylasemia, leukocytosis, and pancreatic-type pain as well as for CT findings of pancreatitis were defined. For each procedure, data related to the patient, technique, clinical course postprocedure, and serum amylase values were prospectively determined and recorded in a database system. Clinical characteristics of the patients (demographics, indications for endoscopic examination), anatomic factors (major papilla, biliary tree, pancreatic ductal system), pancreatic duct opacification, and endoscopic maneuvers were recorded. The types of procedures are shown in Table  1 . Serum amylase value, white blood cell count, and pancreatic-type abdominal pain were recorded for all 1185 procedures, before and after 24 hours. Serum amylase measurements and pancreatic-type pain assessments were also done 6 hours (university institution) and 2, 4, and 8 hours 19 (university-affiliated institution) after the procedure in all cases. Differences in the timing of amylase measurements were related to laboratory availability at each institution. Six-hour and 8-hour findings were considered equivalent. Hyperamylasemia was defined as an increase of the serum enzyme level to greater than the upper normal limit of 220 IU/L. Leukocytosis was defined as a white blood cell count greater than 10,000 cells/mm 3 ; only procedure-related leukocytosis (normal white blood cell count at the time of endoscopy) associated with hyperamylasemia was considered significant. Pancreatic-type pain was defined as a persistent epigastric pain, radiating to the back; pain was evaluated and recorded by an endoscopy staff member who was unaware of the corresponding serum amylase values.
Additional 24-hour follow-up (serum amylase value, white blood cell count, and pancreatic-type pain assessment) was routinely performed in patients whose 24-hour serum amylase was higher than 5 times the upper normal limit and in patients with pancreatic pain at 24 hours, without regard to the serum enzymatic level. An evaluation was routinely carried out at 48 hours (by phone interview in discharged patients) in the remaining cases.
Abdominal CT was routinely performed as the best discriminator for pancreatic inflammation 20 within 48 hours of the onset of symptoms in all patients with pancreatictype pain lasting at least 24 hours and with a 24-hour serum amylase of more than 3 times the upper normal limit. In the university-affiliated institution, CT was also performed in all patients with 24-hour amylase values higher than 5 times the upper normal limit, irrespective of the occurrence of pancreatic-type pain.
The severity of pancreatitis was classified on the basis of either the "Atlanta criteria" 21 or length of hospitalization and complications (2-3 days = mild; 4-10 days = moderate; more than 10 days or complications = severe). 11 Patients were given either standard premedication consisting of pentazocine chloride and hyoscin-N-butyl bromide, intravenously, the dose depending on age and tolerance, or general anesthesia with intravenous propofol (all subjects younger than 18 years and patients who requested general anesthesia). Patients fasted for at least 12 hours after the procedure. For duct opacification iopamidol was injected (Iopamir, Bracco, Milan), a lowosmolality, nonionic contrast medium.
Informed consent was obtained for both performance of the procedures and data collection and management. The protocol was approved by our local ethics committee.
Statistical analysis
The prognostic variables pancreatic-type pain, hyperamylasemia (greater than 3 times and 5 times the upper normal limit), and leukocytosis were considered as independent parameters. Patients' distribution tables according to individual variables were analyzed by the chisquared test, with continuity correction.
RESULTS
Postprocedural hyperamylasemia occurred in 452 cases (38.1%): 351 of 798 therapeutic procedures (44.0%); 83 of 312 diagnostic procedures (26.6%); and 18 of 75 unsuccessful procedures (24.0%). Unsuccessful procedures were those in which neither duct was cannulated. The overall number and percentage of procedures in which serum amylase values, measured 6 to 8 hours and 24 hours after, were normal, greater than 2 times, between 3 and 5 times, or greater than 5 times the upper normal limit, and the occurrence of pancreatic-type pain are reported in Table 2 .
Pancreatic-type pain was not reported in any patients whose serum amylase values were within normal limits or more than twice but less than 3 Six to 8 hours after the procedure, serum amylase value was between 3 and 5 times the upper normal limit in 91 cases (7.7%); and greater than 5 times the upper normal limit in 99 cases (8.3%). Fifty-one of these patients were asymptomatic: 40 of 91 (43.9%) and 11 of 99 (11.1%), with serum amylase value greater than 3 but lower than 5 times the upper normal limit and with 5-fold rise or more, respectively. Pancreatic-type pain, with or without abdominal tenderness, was reported by patients after 139 of 1185 procedures (11.7%): among these patients, 88 (63.3%; 7.4% of the overall cases) had a 5-fold rise or more in the serum amylase value, whereas the remaining 51 had amylase elevations higher than 3 but lower than 5 times the upper normal limit. Pancreatic-type pain was therefore reported by 51 of 91 patients (56.0%) and by 88 of 99 patients (88.9%), with 3-to 5-fold rise and 5-fold rise or more in serum amylase values, respectively.
Twenty-four hours after the procedure, serum amylase levels persisted between 3 and 5 times the upper normal limit in 62 cases (5.2%); values of 5 times the upper normal limit or more were recorded in 82 cases (6.9%). Sixty-six of these patients were asymptomatic, 44 of 62 (71.0%) and 22 of 82 (26.8%) with 3 to 5 and 5-fold rise or more in serum amylase values, respectively. Seventy-eight subjects (6.6%) complained of pancreatic-type pain that persisted 24 hours after the procedure; among these patients, 60 (75.9%; 5.1% of patients overall) had a 5-fold rise or more in serum amylase value, whereas the remaining 18 had amylase values at least 3 but lower than 5 times the upper normal limit. Pancreatic-type pain was therefore reported by 18 of 62 patients (29.0%) and by 60 of 82 patients (73.2%), with 3-to 5-fold rise and 5-fold rise or more in serum amylase values, respectively.
Pancreatic-type pain was significantly (p < 0.001) more frequent either 6 to 8 hours or 24 hours after the procedure in patients with serum amylase values higher than 5 times the upper normal limit than in those with serum amylase values between 3 and 5 times the upper normal limit (Table 3) .
White blood cell count at 24 hours was within the normal limit in the 66 asymptomatic patients with serum amylase values greater than 3 times the upper normal limit (44 and 22 of them had amylase values between 3 and 5 and more than 5 times normal, respectively), and in the 18 patients with pancreatic-type pain associated with serum amylase rise between 3 and 5 times normal. Among the 60 patients with 24-hour pancreatic-type pain and amylase values greater than 5 times the upper normal limit, 25 (41.7%) had elevated white blood cell counts (Table 4) .
CT, performed in the 78 patients with 24-hour pancreatic-type pain associated with amylase values greater than 5 times normal (60 cases) and ranging between 3 and 5 times the normal (18 cases), confirmed the presence of some pancreatic inflammation in 23 of 60 cases (38.3%), but only among those with serum amylase values higher than 5 times the upper normal limit; CT findings were normal in the remaining patients. Seven patients with 24-hour amylase levels higher than 5 times the upper normal limit and without pain also underwent CT in the university-affiliated institution: all had normal CT findings. Figure 1 summarizes the outcome of the 78 patients with 24-hour pancreatic-type pain who underwent CT, in relation to serum amylase level and white blood cell count.
The asymptomatic patients with either 24-hour amylase levels higher than 5 times the normal limit or 24-hour pancreatic-type pain with a serum amylase rise at least 3 times the normal limit underwent additional 24-hour follow-up. Patients with pain were treated with bowel rest, intravenous fluids, and parenteral analgesics, if required. Patients with leukocytosis and/or fever and with CTdocumentated local complications were treated with broad-spectrum antibiotics.
None of the asymptomatic patients with 24-hour amylase values higher than 5 times the upper normal limit nor any of those with 24-hour pancreatic pain associated with serum amylase value between 3 and 5 times the normal limit had symptoms at 48 hours after the endoscopic procedure. At this time, serum amylase values were markedly reduced or within the normal limit in all cases. Among the 60 patients with 24-hour pancreatic-type pain associated with serum amylase rise more than 5 times the normal limit, pain and hyperamylasemia persisted for at least 48 hours in 25 cases (41.7%), whereas in the other cases symptoms disappeared. Figure 2 summarizes the 48-hour outcome of the 60 patients with pancreatic-type pain associated with Figure 1 . Outcome at 48 hours for the 78 patients who underwent CT because of pancreatic-type pain at 24 hours associated with amylase levels either between 3 and 5 times normal or greater than 5 times normal, and white blood cell count either normal or elevated.
amylase levels higher than 5 times the upper normal limit 24 hours after the endoscopic procedure.
Only among the 60 patients with pain at 24 hours and amylase levels greater than 5 times normal were features consistent with clinical pancreatitis (pain persisting 48 hours after the procedure, elevated white blood cell count, or pathologic CT findings). Pancreatitis was graded as mild (2-to 3-day hospital stay for 11 patients; 4-to 10-day hospital stay for 11 patients, all without local or systemic complications), and severe in the remaining 3 patients (more than 10-day hospitalization in 1 case with intrapancreatic fluid collection; more than 30-day hospitalization because of occurrence of peripancreatic fluid collections in 2 not requiring surgical intervention). No systemic complications or pancreatitis-related deaths occurred. In the remaining 35 patients (58.3%), symptoms spontaneously disappeared and amylase elevations were markedly reduced within 36 to 48 hours after the endoscopic procedure.
DISCUSSION
The definition of pancreatitis still remains a controversial issue in relation to post-ERCP/-sphincterotomy complications; the amplitude and duration of serum amylase rise and the occurrence of pancreatic-type pain are crucial points in the definition and grading of the pancreatic reactions.
The rise in serum pancreatic enzymes may vary considerably after ERCP and sphincterotomy without clinical significance. Hyperamylasemia occurs in about 70% of cases within 2 to 4 hours after endoscopic procedures involving the major duodenal papilla, but in most, enzyme values are normal by 24 hours so that hyperamylasemia per se cannot be considered a complication unless the patient also has pain and other signs of pancreatitis. Serum amylasemia more than 5 times the upper normal limit lasting for 24 hours after the endoscopic procedure, although suggesting some pancreatic involvement, occurred in the absence of clinical symptoms in about 27% of cases evaluated in the universityaffiliated institution 22 ; this serum enzymatic rise should therefore still be considered only a transient postprocedural finding.
It is generally agreed that epigastric pain radiating to the back in the postprocedural period, with or without abdominal tenderness, is a reliable indicator of some pancreatic inflammation. The duration of pain is crucial for defining pancreatitis because pain that disappears within 24 hours is unlikely to indicate pancreatitis and is probably due to some transient pancreatic reaction or other causes, such as intolerance to air insufflated during the procedure. Moreover, mild pain persisting at 24 hours but disappearing within the subsequent 12 to 24 hours and not requiring analgesics or a prolonged hospital stay still does not fulfill the criteria for defining clinical pancreatitis. In fact, excluding those few cases of moderate to severe pancreatitis requiring hospitalization for more than 3 days or cases with complications, the distinction between clinical mild pancreatitis and hyperamylasemia with transient abdominal discomfort seems to be more elusive. It has been proposed that epigastric pain, as an indicator of pancreatitis in the postprocedure period, must persist for at least 24 hours, [1] [2] [3] 7, 11, 13, 14, 17 at least 48 hours, 4, 15, 16 or should require hospitalization of more than 48 hours. 18, 23 In another study, no mention is made of the duration of pain and length of hospital stay in cases classified as having postprocedure pancreatitis, 5 whereas in other reports patients with pain had to require narcotic analgesics to be consistent for pancreatitis. 1, 2 An attempt was made a few years ago 11 to establish reliable criteria for defining this complication, leading to a consensus statement based on more than 15,000 procedures; pancreatic-type pain associated with at least a 3-fold increase in serum amylase persisting 24 hours after the endoscopic procedure was considered an indicator of pancreatitis. However, the criteria proposed have not been widely adopted since then, even in some of the largest series published. 4, 5 Our study prospectively evaluated the 48-hour clinical and enzymatic course after endoscopic procedures involving the major duodenal papilla in a large series of consecutive patients and was designed to identify 24-hour clinical and enzymatic findings really consistent for acute pancreatitis on the basis of CT, white blood cell count, and an additional 24-hour follow-up period.
As previously reported, postprocedure hyperamylasemia occurred in about 40% of cases and was more frequent after therapeutic (44.0%) than diagnostic (26.6%) ERCP. Unsuccessful cannulation was also associated with hyperamylasemia in 24.0% of cases. Pancreatic-type pain was not reported by any patients whose serum amylase value was less than 3 times the upper normal limit over the initial 24-hour follow-up period.
Six to 8 hours after the procedure, pain was reported by 11.7% of patients; it occurred in 56% of patients with a serum amylase rise between 3 and 5 times normal and in 88.9% of those with hyperamylasemia greater than 5 times normal. Twenty-four hours after the procedure, pain was still reported by 6.6% of patients, but only 29% of those had amylase levels between 3 and 5 times normal; 73.2% of those with amylase levels greater than 5 times normal had pain. Pain was reported in a significantly higher proportion of patients (p < 0.001) with amylase levels higher than 5 times normal, either 6 to 8 hours or 24 hours after the procedure. The numbers and percentages of patients with 24-hour pain associated with amylase levels between 3 and 5 times normal were reduced by 64.7% and 48.2%, respectively, in comparison with 6-to 8-hour findings; on the other hand, the number and percentage of patients with 24-hour pain associated with amylase levels greater than 5 times normal were reduced only by 31.8% and 17.2%, respectively. Six-to 8-hour amylase values greater than 5 times normal with pain was therefore a finding more frequently associated with persistence of the pancreatic reaction at 24 hours, as previously reported. 22 Persistence of pain and hyperamylasemia for 24 hours is of crucial importance in defining postprocedure pancreatitis and is considered reliable criteria in most published studies. However, prospective studies have suggested that pancreatic-type pain associated with a 24-hour serum enzymatic increase 2, 3, 4, or 5 times the upper normal limit is enough to define pancreatitis. This leads to a varying incidence of pancreatitis in published series, depending on the adopted criteria, and to some confusion about which findings should be really considered consistent for pancreatitis.
None of our patients with 24-hour pain associated with serum enzymatic rise between 3 and 5 times normal showed leukocytosis and still had pain 48 hours after the procedure; at this time, serum amylase level was markedly reduced or within the normal range in all cases. CT findings were also normal in all cases.
In contrast, among those patients with 24-hour pain associated with hyperamylasemia greater than 5 times normal, leukocytosis occurred in 41.7% of cases; in the same percentage of cases pain and hyperamylasemia persisted 48 hours after the endoscopic procedure; CT documented some pancreatic involvement only in this group of patients. Although 24-hour leukocytosis was documented in less than half of these cases, it was associated with 48-hour moderate-to-severe pancreatitis in 48% of cases, whereas absence of leukocytosis was associated with moderate, but not severe, pancreatitis in only 5.7% of cases. Therefore, 24-hour leukocytosis should be considered a predictor of some clinically relevant form of pancreatitis.
In conclusion, our study indicates that only patients with 24-hour pancreatic-type pain and amylase levels greater than 5 times normal limit had leukocytosis, CT findings of some pancreatic involvement, and persistence of pain over a period of 48 hours after the procedure. All of these patients must therefore be followed carefully for an additional 24-hour period to identify those who will have clinically relevant pancreatitis develop. On the other hand, 24-hour pancreatic-type pain associated with amylase levels between 3 and 5 times the upper normal limit was never associated in our cases with leukocytosis, CT-documented pancreatic involvement, or persistence of symptoms 48 hours
